NEK2的低表达与肝细胞癌进展及不良预后相关。

Low expression of NEK2 is associated with hepatocellular carcinoma progression and poor prognosis.

作者信息

Fu Luoqin, Liu Suxia, Wang Huiju, Ma Yingyu, Li Li, He Xianglei, Mou Xiaozhou, Tong Xiangmin, Hu Zhiming, Ru Guoqing

机构信息

Clinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou 310014, Zhejiang, China.

School of Medicine, Zhejiang University, Hangzhou 310000, Zhejiang, China.

出版信息

Cancer Biomark. 2017 Jul 19;20(1):101-106. doi: 10.3233/CBM-170586.

DOI:10.3233/CBM-170586

PMID:28759960

Abstract

BACKGROUND

NIMA-related kinase 2 (NEK2), a serine/threonine kinase, is located in the centrosome and is a member of cell cycle regulation related protein kinase (CCRK) family. Aberrant expression of NEK2 is linked with carcinogenesis and progression of various tumors.

OBJECTIVE

To investigate the expression level of NEK2 and its relationship with clinicopathological factors in hepatocellular carcinoma (HCC).

METHODS

Immunohistochemistry was used to measure the expression of NEK2 in 310 patients' specimen tissues and 197 adjacent normal liver tissues of HCC cases, and the subsequent prognostic value for each sample was estimated.

RESULTS

NEK2 expression levels in HCC were lower than in adjacent tissues (49.7% vs. 72.6%, P< 0.001). First, patients with relatively low NEK2 expression had increased cancer progression and poorer prognosis than those with high expression. Second, NEK2 expression was significantly reduced in patients with large tumors (P= 0.025), with stage III Edmondson-Steiner Grading (P= 0.015). Third, patients' tumor size positively correlated with high AFP concentration (P= 0.017). Fourth, using the Kaplan-Meier survival curve, we found a lower survival rate in patients with decreased expression of NEK2 than those with high NEK2 expression in HCC (P= 0.029, Log-rank test).

CONCLUSIONS

Low NEK2 expression might be a useful predictor in HCC as a poor prognostic factor, and could serve as a potential therapeutic target for HCC.

摘要

背景

NIMA相关激酶2（NEK2）是一种丝氨酸/苏氨酸激酶，位于中心体，是细胞周期调控相关蛋白激酶（CCRK）家族的成员。NEK2的异常表达与多种肿瘤的发生和进展有关。

目的

研究NEK2在肝细胞癌（HCC）中的表达水平及其与临床病理因素的关系。

方法

采用免疫组织化学法检测310例患者的标本组织及197例HCC病例的癌旁正常肝组织中NEK2的表达，并评估每个样本的后续预后价值。

结果

HCC中NEK2的表达水平低于癌旁组织（49.7%对72.6%，P<0.001）。首先，NEK2表达相对较低的患者比高表达患者的癌症进展更快，预后更差。其次，大肿瘤患者（P=0.025）、Edmondson-Steiner分级III期患者（P=0.015）的NEK2表达明显降低。第三，患者的肿瘤大小与高AFP浓度呈正相关（P=0.017）。第四，使用Kaplan-Meier生存曲线，我们发现HCC中NEK2表达降低的患者的生存率低于NEK2高表达的患者（P=0.029，对数秩检验）。